154 related articles for article (PubMed ID: 38707930)
21. French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial.
Lima PB; Dias JAF; Esposito ACC; Miot LDB; Miot HA
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):502-508. PubMed ID: 32841433
[TBL] [Abstract][Full Text] [Related]
22. Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor-blind split-face controlled trial.
Poostiyan N; Alizadeh M; Shahmoradi Z; Fatemi Naeini F
J Cosmet Dermatol; 2023 Apr; 22(4):1238-1244. PubMed ID: 36606390
[TBL] [Abstract][Full Text] [Related]
23. Clinical assessment of a circadian-based antioxidant system combined with a comprehensive brightening serum in diverse subjects with moderate-to-severe facial hyperpigmentation.
Shah S; Manry S; Makino ET; Mehta RC
J Cosmet Dermatol; 2022 May; 21(5):2082-2088. PubMed ID: 35287252
[TBL] [Abstract][Full Text] [Related]
24. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
Grimes PE
Cutis; 2004 Dec; 74(6):362-8. PubMed ID: 15663072
[TBL] [Abstract][Full Text] [Related]
25. A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma.
Fabi SG; Friedmann DP; Niwa Massaki AB; Goldman MP
Lasers Surg Med; 2014 Sep; 46(7):531-7. PubMed ID: 24895301
[TBL] [Abstract][Full Text] [Related]
26. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy.
Cestari TF; Hexsel D; Viegas ML; Azulay L; Hassun K; Almeida AR; Rêgo VR; Mendes AM; Filho JW; Junqueira H
Br J Dermatol; 2006 Dec; 156 Suppl 1():13-20. PubMed ID: 17176300
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability on melasma of a topical cosmetic product acting on melanocytes, fibroblasts and endothelial cells: a randomized comparative trial against 4% hydroquinone.
Bronzina E; Clement A; Marie B; Fook Chong KT; Faure P; Passeron T
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):897-903. PubMed ID: 31858658
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study.
El-Husseiny R; Rakha N; Sallam M
Dermatol Ther; 2020 Nov; 33(6):e14240. PubMed ID: 32856757
[TBL] [Abstract][Full Text] [Related]
29. Hydroquinone-free Skin Brightener System for the Treatment of Moderate-to-severe Facial Hyperpigmentation.
Herndon JH; Makino ET; Stephens TJ; Mehta RC
J Clin Aesthet Dermatol; 2014 May; 7(5):27-31. PubMed ID: 24847406
[TBL] [Abstract][Full Text] [Related]
30. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
Fabi SG; Goldman MP
J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
[TBL] [Abstract][Full Text] [Related]
31. Novel skin brightener used as monotherapy for moderate melasma in skin of color.
Grimes PE
J Drugs Dermatol; 2014 Mar; 13(3):364-6. PubMed ID: 24595584
[TBL] [Abstract][Full Text] [Related]
32. Split-face comparison of hydroquinone 4% plus nitrogen plasma vs. hydroquinone 4% alone in the treatment of melasma.
Yousefi M; Hadian K; Babossalam S; Diab R; Akhlaghi M; Aghighi M; Abdollahimajd F; Shokri B
Lasers Med Sci; 2023 Apr; 38(1):113. PubMed ID: 37103690
[TBL] [Abstract][Full Text] [Related]
33. Combined use of two formulations containing diacetyl boldine, TGF-β1 biomimetic oligopeptide-68 with other hypopigmenting/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin.
Pratchyapurit WO
J Cosmet Dermatol; 2016 Jun; 15(2):131-44. PubMed ID: 26833454
[TBL] [Abstract][Full Text] [Related]
34. Fractional 1064 nm Picosecond Laser in Treatment of Melasma and Skin Rejuvenation in Asians, A Prospective Study.
Wong CSM; Chan MWM; Shek SYN; Yeung CK; Chan HHL
Lasers Surg Med; 2021 Oct; 53(8):1032-1042. PubMed ID: 33544930
[TBL] [Abstract][Full Text] [Related]
35. Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
Mokhtari F; Bahrami B; Faghihi G; Asilian A; Iraji F
J Dermatolog Treat; 2022 Aug; 33(5):2475-2481. PubMed ID: 34387527
[TBL] [Abstract][Full Text] [Related]
36. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians.
Wattanakrai P; Mornchan R; Eimpunth S
Dermatol Surg; 2010; 36(1):76-87. PubMed ID: 20298254
[TBL] [Abstract][Full Text] [Related]
37. Extension Phase of a Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang JV; Fabi SG; Robinson DM; Bajaj S; Geronemus RG; Bell M; Robison T; Widgerow AD
J Drugs Dermatol; 2024 Jan; 23(1):1266-1270. PubMed ID: 38206144
[TBL] [Abstract][Full Text] [Related]
38. Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of
Goh CL; Chuah SY; Tien S; Thng G; Vitale MA; Delgado-Rubin A
J Clin Aesthet Dermatol; 2018 Mar; 11(3):14-19. PubMed ID: 29606995
[No Abstract] [Full Text] [Related]
39. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma.
Arrowitz C; Schoelermann AM; Mann T; Jiang LI; Weber T; Kolbe L
J Invest Dermatol; 2019 Aug; 139(8):1691-1698.e6. PubMed ID: 30825454
[TBL] [Abstract][Full Text] [Related]
40. A randomized, open-label study to compare two different dosing regimens of oral tranexamic acid in treatment of moderate to severe facial melasma.
Bhattacharjee R; Hanumanthu V; Thakur V; Bishnoi A; Vinay K; Kumar A; Parsad D; Kumaran MS
Arch Dermatol Res; 2023 Aug; 315(6):1831-1836. PubMed ID: 36757440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
